NIKKEI 225
38,174.75 -99.30 (-0.26%) HANG SENG
17,763.03 0.00 (0.00%) CRUDE OIL
79.18 +0.18 (+0.23%) GOLD FUTURES
2,335.80 +24.80 (+1.07%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,050.33 -1,691.70 (-3.54%)
Alto Neuroscience, Inc. (ANRO)
After hours:
| Previous close | 15.51 |
| Open | 15.38 |
| Bid | 16.28 x 1100 |
| Ask | 19.50 x 1100 |
| Day's range | 14.91 - 16.53 |
| 52-week range | 12.78 - 24.00 |
| Volume | |
| Avg. volume | 260,616 |
| Market cap | 432.832M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.33 |
Business WireAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
LOS ALTOS, Calif., April 23, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS). Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administration. The TDS formulation is being developed
ZacksAlto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
Alto Neuroscience (ANRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Business WireAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
LOS ALTOS, Calif., April 03, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics. To date, ALTO-203 has demonstrated positive emotional and cognitive effects in healthy participants after a single dose. The present study will evaluate these effects in patients with MDD to d
